Approval · Notice of Compliance 22951 · 2019
APIDRA: Notice of Compliance 22951
Issued November 26, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22951
- Date
- November 26, 2019
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- Labelling updates
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APIDRA | Not yet assigned | — |
Medicinal ingredients
- INSULIN GLULISINE (RECOMBINANT DNA ORIGIN) 100 UNIT per ML